CRIS Current Research Information System

PALANDRI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.380
AS - Asia 7.690
EU - Europa 5.566
AF - Africa 462
SA - Sud America 439
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 3
Totale 22.555
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.273
SG - Singapore 2.063
VN - Vietnam 2.046
CN - Cina 1.953
GB - Regno Unito 1.326
IT - Italia 860
SE - Svezia 842
DE - Germania 714
HK - Hong Kong 435
IN - India 401
FR - Francia 373
BR - Brasile 315
RU - Federazione Russa 302
IE - Irlanda 218
NL - Olanda 218
JP - Giappone 202
UA - Ucraina 162
FI - Finlandia 138
KR - Corea 138
ZA - Sudafrica 132
CI - Costa d'Avorio 120
EE - Estonia 103
TG - Togo 98
CA - Canada 65
JO - Giordania 63
CH - Svizzera 56
BG - Bulgaria 54
PH - Filippine 51
TR - Turchia 48
BE - Belgio 47
BD - Bangladesh 42
AR - Argentina 39
TH - Thailandia 39
PL - Polonia 38
NG - Nigeria 36
ID - Indonesia 35
TW - Taiwan 34
MX - Messico 26
AT - Austria 25
IQ - Iraq 25
EC - Ecuador 24
IR - Iran 24
ES - Italia 19
CL - Cile 16
PK - Pakistan 16
SC - Seychelles 16
CZ - Repubblica Ceca 14
SA - Arabia Saudita 13
AU - Australia 12
MA - Marocco 11
VE - Venezuela 11
CO - Colombia 10
ET - Etiopia 10
GR - Grecia 10
LB - Libano 10
PY - Paraguay 10
AE - Emirati Arabi Uniti 9
LT - Lituania 9
EG - Egitto 8
KE - Kenya 8
RO - Romania 8
UZ - Uzbekistan 8
DZ - Algeria 7
PE - Perù 7
DK - Danimarca 6
IL - Israele 6
LV - Lettonia 6
MY - Malesia 6
TN - Tunisia 6
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
HR - Croazia 3
JM - Giamaica 3
NP - Nepal 3
NZ - Nuova Zelanda 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
CR - Costa Rica 2
CY - Cipro 2
GH - Ghana 2
GT - Guatemala 2
KG - Kirghizistan 2
LY - Libia 2
NO - Norvegia 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
BB - Barbados 1
CG - Congo 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GF - Guiana Francese 1
GI - Gibilterra 1
Totale 22.542
Salva come PNG Salva come JPEG
Città #
Singapore 1.422
Southend 1.166
Ashburn 887
Fairfield 820
Chandler 741
San Jose 500
Hong Kong 415
Dong Ket 414
Seattle 399
Ho Chi Minh City 392
Hanoi 389
Houston 385
Wilmington 374
Woodbridge 372
Beijing 312
Cambridge 306
Princeton 279
Ann Arbor 246
Hefei 239
Santa Clara 233
Dublin 218
Bologna 176
Boardman 175
Tokyo 168
Lauterbourg 141
Dallas 138
Nanjing 128
Abidjan 120
Los Angeles 118
Helsinki 115
Westminster 114
Seoul 113
Lomé 98
Padova 97
New York 96
Milan 82
Jacksonville 78
Jinan 74
Berlin 68
Munich 65
Buffalo 63
Amman 62
Council Bluffs 62
Shenyang 61
Bremen 60
Turin 60
Saint Petersburg 56
Haiphong 53
Sofia 53
Da Nang 51
Frankfurt am Main 49
Brussels 46
Redondo Beach 46
Bern 45
Hyderabad 44
San Diego 43
Falls Church 42
Redmond 38
Changsha 37
São Paulo 37
Guangzhou 36
Shanghai 36
Abeokuta 33
Nanchang 33
Cornaredo 32
Falkenstein 32
Warsaw 30
Medford 29
Zhengzhou 29
Hangzhou 28
Chicago 26
Jiaxing 26
Rome 26
Bengaluru 25
Johannesburg 25
Nuremberg 25
Tianjin 25
Des Moines 24
Hebei 24
Florence 23
London 23
Orem 23
Biên Hòa 22
Redwood City 22
Chengdu 21
Can Tho 20
Dearborn 20
Jakarta 20
Norwalk 20
Phoenix 20
Toronto 20
Montreal 19
Haikou 18
Burdur 17
Olalla 16
Stockholm 16
Brooklyn 15
The Dalles 15
Yubileyny 15
Amsterdam 14
Totale 14.624
Salva come PNG Salva come JPEG
Nome #
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 300
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 289
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 279
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 257
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 251
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 243
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 238
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 234
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 226
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 220
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 218
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 213
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 212
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 211
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 209
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 209
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 204
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 204
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 201
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 200
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 197
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 197
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 192
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 192
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 189
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 187
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 186
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 186
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 185
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 184
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 183
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 183
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 183
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 182
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 179
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 179
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability 176
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 176
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 175
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 175
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 174
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 173
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. 169
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 167
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 166
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 166
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 166
The “vesicular intelligence” strategy of blood cancers 166
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 165
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 164
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 163
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 162
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 162
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 159
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 158
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 157
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 156
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 156
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 155
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 154
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 154
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 153
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 152
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 151
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 151
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 145
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 145
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 143
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 142
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 141
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 140
Diagnosis and classification of the risk 140
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 140
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 139
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 138
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 138
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 137
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 137
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance 136
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 136
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 135
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 134
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 134
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 134
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 133
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 132
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 131
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 130
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 129
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 129
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 128
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 127
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 127
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 127
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 126
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 125
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 125
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 124
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors 122
Totale 17.079
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.862
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.862
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021903 0 0 0 0 0 0 0 0 0 79 145 679
2021/20222.634 210 66 147 281 219 144 56 192 96 268 501 454
2022/20232.919 338 441 176 391 194 243 88 167 477 93 195 116
2023/2024909 57 135 55 87 63 186 56 61 33 67 56 53
2024/20253.256 163 421 260 279 367 166 233 132 86 298 137 714
2025/20266.981 579 610 718 509 824 420 700 456 1.654 511 0 0
Totale 23.037